CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 113 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $55,210,602 | -30.9% | 2,529,116 | +0.6% | 1.48% | -22.2% |
Q2 2023 | $79,917,390 | +30.3% | 2,513,916 | 0.0% | 1.90% | +29.9% |
Q1 2023 | $61,314,411 | -22.4% | 2,513,916 | +0.3% | 1.46% | -23.1% |
Q4 2022 | $79,053,875 | +11.9% | 2,506,464 | +0.3% | 1.90% | +4.3% |
Q3 2022 | $70,626,000 | +51.2% | 2,499,148 | +41.4% | 1.82% | +34.1% |
Q2 2022 | $46,723,000 | -22.6% | 1,767,141 | +2.5% | 1.36% | -10.5% |
Q1 2022 | $60,334,000 | +12.9% | 1,723,341 | +4.5% | 1.52% | +23.0% |
Q4 2021 | $53,442,000 | +13.2% | 1,648,435 | +3.0% | 1.24% | +24.4% |
Q3 2021 | $47,217,000 | +81.2% | 1,600,589 | +57.4% | 0.99% | +92.8% |
Q2 2021 | $26,054,000 | +88.8% | 1,016,945 | +1.2% | 0.52% | +71.1% |
Q1 2021 | $13,800,000 | -16.7% | 1,005,100 | +0.6% | 0.30% | -14.2% |
Q4 2020 | $16,563,000 | – | 999,000 | – | 0.35% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,713,470,000 | 41.39% |
Perceptive Advisors | 6,511,727 | $184,021,000 | 5.34% |
Finepoint Capital LP | 536,901 | $15,173,000 | 4.99% |
Artal Group S.A. | 2,000,000 | $56,520,000 | 2.41% |
Rock Springs Capital Management LP | 2,499,148 | $70,626,000 | 1.82% |
Ikarian Capital, LLC | 178,100 | $5,033,000 | 1.00% |
Hood River Capital Management LLC | 896,572 | $25,337,000 | 0.97% |
Frazier Life Sciences Management, L.P. | 393,000 | $11,106,000 | 0.86% |
HighVista Strategies LLC | 23,611 | $667,000 | 0.38% |
FEDERATED HERMES, INC. | 3,313,333 | $93,635,000 | 0.27% |